SEC Comment Letter 0000000000-24-003591 to Checkpoint Therapeutics, Inc. (CKPT) (CIK 0001651407)
Checkpoint Therapeutics, Inc. (CKPT) (CIK 0001651407)
Date: April 3, 2024 · CIK: 0001651407 · Accession: 0000000000-24-003591
AI Filing Summary & Sentiment
File numbers found in text: 333-278397
Letter
United States securities and exchange commission logo April 3, 2024 James F. Oliviero Chief Executive Officer Checkpoint Therapeutics, Inc. 95 Sawyer Road, Suite 110 Waltham, MA 02453 Re:Checkpoint Therapeutics, Inc. Registration Statement on Form S-3 Filed March 29, 2024 File No. 333-278397 Dear James F. Oliviero: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew W. Mamak, Esq.
Show Raw Text
United States securities and exchange commission logo
April 3, 2024
James F. Oliviero
Chief Executive Officer
Checkpoint Therapeutics, Inc.
95 Sawyer Road, Suite 110
Waltham, MA 02453
Re:Checkpoint Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 29, 2024
File No. 333-278397
Dear James F. Oliviero:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew W. Mamak, Esq.